Vigilant Biosciences Announces Poster Presentation at the Boston University / Dana-Farber Head & Neck Cancer Symposium

Vigilant Biosciences Announces Poster Presentation at the Boston University / Dana-Farber Head & Neck Cancer Symposium August 7, 2018 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the upcoming presentation of an abstract regarding the Sylvester Comprehensive

Oral Squamous-Cell Carcinoma Detection

Oral Squamous-Cell Carcinoma Detection September 8, 2015 Who is at risk? Everyone!Oral Squamous Cell Carcinoma (OSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC) have confounded the health-care profession for a long time. More than 90 percent of HNSCC are OSCC. According to the Oral Cancer Foundation, approximately 44,000 Americans will be diagnosed with oral

Vigilant Biosciences Announces Exclusive Distribution Agreement with Crown Dental + Medical Limited in New Zealand

Vigilant Biosciences Announces Exclusive Distribution Agreement with Crown Dental + Medical Limited in New Zealand September 2, 2015 Vigilant Biosciences Inc. (Fort Lauderdale, Florida) has announced it has entered into a three-year exclusive sales and marketing agreement with Crown Dental + Medical Limited (Aukland, New Zealand) for the distribution of the OncAlert Oral Cancer Risk Assessment System in New Zealand.

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev C